Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer

Archives of Otolaryngology - Head and Neck Surgery

Volumn 136, Issue 12, 2010, Pages 1267-1273

  Wansom, Derrick ^a   Light, Emily ^a   Worden, Frank ^a   Prince, Mark ^a   Urba, Susan ^a   Chepeha, Douglas B ^a   Cordell, Kitrina ^a   Eisbruch, Avraham ^a   Taylor, Jeremy ^a   D'Silva, Nisha ^a   Moyer, Jeffrey ^a   Bradford, Carol R ^a   Kurnit, David ^a   Kumar, Bhavna ^a   Carey, Thomas E ^a   Wolf, Gregory T ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; PACLITAXEL;

ADVANCED CANCER; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NATURAL KILLER CELL; OROPHARYNX CANCER; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PROGNOSIS; T LYMPHOCYTE SUBPOPULATION;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; COMBINED MODALITY THERAPY; DNA, VIRAL; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNITY, CELLULAR; NEOADJUVANT THERAPY; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 78650850522     PISSN: 08864470     EISSN: 1538361X     Source Type: Journal    
DOI: 10.1001/archoto.2010.211     Document Type: Article

References (23)

1. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2006;24(17):2606-2611. (Pubitemid 46622080)
2. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009;15(22):6758-6762.
3. Wolf GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otolaryngol Head Neck Surg. 1986;95(2):142-152.
4. Rapidis A, Wolf GT. Immunotherapy of head and neck cancer: current and future considerations. J Oncol. 2009;2009:346345. doi:10.1155/2009/346345.
5. Wolf GT, Schmaltz S, Hudson J, et al. Alterations in T-lymphocyte subpopulations in patients with head and neck squamous carcinoma: correlations with prognosis. Arch Otolaryngol Head Neck Surg. 1987;113(11):1200-1206.
6. Hoffmann TK, Arsov C, Schirlau K, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer. 2006;118(8):1984-1991.
7. 264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10(20):6929-6937.
8. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg. 2009;135(11):1137-1146.
9. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associated with HPV16 copy number. J Clin Oncol. 2008;26(19):3138-3146.
10. Yang H, Yang K, Khafagi A, et al. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A. 2005;102(21):7683-7688.
11. Obiso R, Lorincz A. Digene Corporation. Pharmacogenomics. 2004;5(1):129-132.
12. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128-3137.
13. Frazer IH. Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology. 2009;384(2):410-414.
14. Arends MJ, Benton EC, McLaren KM, Stark LA, Hunter JA, Bird CC. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer. 1997;75(5):722-728.
15. Ressing ME, van Driel WJ, Celis E, et al. Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res. 1996;56(3):582-588.
16. Rizzuto GA, Merghoub T, Hirschhorn-Cymerman D, et al. Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med. 2009;206(4):849-866.
17. Alhamarneh O, Amarnath SMP, Stafford ND, Greenman J. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck. 2008;30(2):251-261. (Pubitemid 351251710)
18. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 2000;121(2):216-225. (Pubitemid 30662070)
19. Trimble C, Lin CT, Hung CF, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine. 2003;21(25-26):4036-4042.
20. Smith KA, Meisenburg BL, Tam VL, et al. Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors. Clin Cancer Res. 2009;15(19):6167-6176.
21. Wolf GT, Chretien PB, Weiss JF, Edwards BK, Spiegel HE. Effects of smoking and age on serum levels of immune reactive proteins. Otolaryngol Head Neck Surg. 1982;90(3, pt 1):319-326.
22. Duffy SA, Ronis DL, McLean S, et al. Pretreatment health behaviors predict survival among patients with head and neck squamous cell carcinoma. J Clin Oncol. 2009;27(12):1969-1975.
23. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16(4):1226-1235.